PL1960429T3 - Immunoglobuliny skierowane przeciwko nogo - Google Patents

Immunoglobuliny skierowane przeciwko nogo

Info

Publication number
PL1960429T3
PL1960429T3 PL06830633T PL06830633T PL1960429T3 PL 1960429 T3 PL1960429 T3 PL 1960429T3 PL 06830633 T PL06830633 T PL 06830633T PL 06830633 T PL06830633 T PL 06830633T PL 1960429 T3 PL1960429 T3 PL 1960429T3
Authority
PL
Poland
Prior art keywords
directed against
immunoglobulins directed
against nogo
nogo
immunoglobulins
Prior art date
Application number
PL06830633T
Other languages
English (en)
Inventor
Stephanie Jane Clegg
Jonathan Henry Ellis
Volker Germaschewski
Paul Andrew Hamblin
George Kopsidas
Ruth Mcadam
Rabinder Kumar Prinjha
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35736284&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL1960429(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of PL1960429T3 publication Critical patent/PL1960429T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
    • C07K16/464—Igs containing CDR-residues from one specie grafted between FR-residues from another
    • C07K16/465—Igs containing CDR-residues from one specie grafted between FR-residues from another with additional modified FR-residues
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
PL06830633T 2005-12-16 2006-12-14 Immunoglobuliny skierowane przeciwko nogo PL1960429T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB0525662.3A GB0525662D0 (en) 2005-12-16 2005-12-16 Immunoglobulins
PCT/EP2006/069737 WO2007068750A2 (en) 2005-12-16 2006-12-14 Immunoglobulins directed against nogo
EP06830633A EP1960429B1 (en) 2005-12-16 2006-12-14 Immunoglobulins directed against nogo

Publications (1)

Publication Number Publication Date
PL1960429T3 true PL1960429T3 (pl) 2012-11-30

Family

ID=35736284

Family Applications (1)

Application Number Title Priority Date Filing Date
PL06830633T PL1960429T3 (pl) 2005-12-16 2006-12-14 Immunoglobuliny skierowane przeciwko nogo

Country Status (31)

Country Link
US (2) US8362208B2 (pl)
EP (2) EP1960429B1 (pl)
JP (1) JP5015949B2 (pl)
KR (1) KR101355118B1 (pl)
CN (1) CN101374863B (pl)
AR (1) AR057239A1 (pl)
AU (1) AU2006325228B2 (pl)
BR (1) BRPI0619855A2 (pl)
CA (1) CA2633501C (pl)
CR (1) CR10099A (pl)
CY (1) CY1113094T1 (pl)
DK (1) DK1960429T3 (pl)
EA (1) EA015536B1 (pl)
ES (1) ES2389380T3 (pl)
GB (1) GB0525662D0 (pl)
HK (1) HK1119720A1 (pl)
HR (1) HRP20120684T1 (pl)
IL (1) IL192086A0 (pl)
JO (1) JO2795B1 (pl)
MA (1) MA30041B1 (pl)
MY (1) MY149492A (pl)
NO (1) NO20082699L (pl)
NZ (1) NZ569143A (pl)
PE (1) PE20071099A1 (pl)
PL (1) PL1960429T3 (pl)
PT (1) PT1960429E (pl)
SI (1) SI1960429T1 (pl)
TW (1) TWI378940B (pl)
UA (1) UA96279C2 (pl)
WO (1) WO2007068750A2 (pl)
ZA (2) ZA200805111B (pl)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2009258063B2 (en) 2007-06-21 2014-09-25 Macrogenics, Inc. BCR-complex-specific antibodies and methods of using same
WO2009056509A1 (en) 2007-11-02 2009-05-07 Novartis Ag Improved nogo-a binding molecules and pharmaceutical use thereof
UY31807A (es) 2008-05-06 2009-12-14 Glaxo Group Ltd Encapsulación de agentes biológicamente activos
WO2010004031A2 (en) * 2008-07-11 2010-01-14 Glaxo Group Limited Novel treatment
US8828390B2 (en) 2010-07-09 2014-09-09 Universitat Zurich Uses of NOGO-A inhibitors and related methods
EP2870177A1 (en) 2012-07-05 2015-05-13 Glaxo Group Limited Optimum dose regime of an anti-nogo-a antibody in the treatment of amyotrophic lateral sclerosis
US20180362660A1 (en) * 2016-05-09 2018-12-20 Schickwann Tsai Anti-penumbra monoclonal antibodies for detection and therapy of normal and abnormal B lymphocytes
WO2018232144A1 (en) * 2017-06-14 2018-12-20 Monojul, Llc High-affinity anti-human folate receptor beta antibodies and methods of use
CN114599676A (zh) 2019-10-24 2022-06-07 诺华康制药股份公司 新型抗-Nogo-A抗体
GB202012331D0 (en) 2020-08-07 2020-09-23 Petmedix Ltd Therapeutic antibodies
WO2022263864A1 (en) 2021-06-17 2022-12-22 Petmedix Ltd Anti canine cd20 antibodies
WO2023067358A1 (en) 2021-10-21 2023-04-27 Petmedix Ltd Proteins comprising the extracellular domain of p75ntr
CN116251181B (zh) * 2021-12-02 2023-09-22 北京东方百泰生物科技股份有限公司 一种抗tslp单克隆抗体的注射制剂
WO2023152486A1 (en) 2022-02-09 2023-08-17 Petmedix Ltd Therapeutic antibodies
WO2024041450A1 (zh) * 2022-08-22 2024-02-29 舒泰神（北京）生物制药股份有限公司 特异性识别Nogo-A的抗体及其应用

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS57106673A (en) 1980-12-24 1982-07-02 Chugai Pharmaceut Co Ltd Dibenzo(b,f)(1,4)oxazepin derivative
DD266710A3 (de) 1983-06-06 1989-04-12 Ve Forschungszentrum Biotechnologie Verfahren zur biotechnischen Herstellung van alkalischer Phosphatase
US5807715A (en) 1984-08-27 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
US4879231A (en) 1984-10-30 1989-11-07 Phillips Petroleum Company Transformation of yeasts of the genus pichia
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
GB8610600D0 (en) 1986-04-30 1986-06-04 Novo Industri As Transformation of trichoderma
EP0307434B2 (en) 1987-03-18 1998-07-29 Scotgen Biopharmaceuticals, Inc. Altered antibodies
US4873316A (en) 1987-06-23 1989-10-10 Biogen, Inc. Isolation of exogenous recombinant proteins from the milk of transgenic mammals
US5250414A (en) 1988-11-04 1993-10-05 Erziehungsdirektion Of The Canton Zurich Diagnostic methods using neurite growth regulatory factors
EP0402226A1 (en) 1989-06-06 1990-12-12 Institut National De La Recherche Agronomique Transformation vectors for yeast yarrowia
WO1993008829A1 (en) 1991-11-04 1993-05-13 The Regents Of The University Of California Compositions that mediate killing of hiv-infected cells
EP0656064B1 (en) 1992-08-17 1997-03-05 Genentech, Inc. Bispecific immunoadhesins
GB9403250D0 (en) 1994-02-21 1994-04-13 Univ Mcgill Therapeutic use of myelin-associated glycoprotein (mag)
US5429746A (en) 1994-02-22 1995-07-04 Smith Kline Beecham Corporation Antibody purification
ATE273959T1 (de) 1994-05-27 2004-09-15 Glaxosmithkline Spa Chinolinderivate als tachykinin nk3 rezeptor antagonisten
GB9424449D0 (en) 1994-12-02 1995-01-18 Wellcome Found Antibodies
WO1997001352A1 (en) 1995-06-27 1997-01-16 Research Foundation Of Cuny, Hunter College Compositions and methods using myelin-associated glycoprotein (mag) and inhibitors thereof
US6420338B1 (en) * 1997-06-13 2002-07-16 New York University Medical Center Inhibition of the Src kinase family pathway as a method of treating HBV infection and hepatocellular carcinoma
GB9809839D0 (en) 1998-05-09 1998-07-08 Glaxo Group Ltd Antibody
DE69942803D1 (de) 1998-07-22 2010-11-11 Smithkline Beecham Ltd Rotein änhelt, und dafür kodierende cdns
MXPA01004598A (es) 1998-11-06 2002-04-24 Martin E Schwab Secuencias de nucleotidos y proteinas de los genes nogo y metodos basados en estas.
FR2792199B3 (fr) 1999-04-13 2001-05-18 Sanofi Sa Utilisation de l'osanetant pour la preparation de medicaments utiles dans le traitement des troubles de l'humeur
EP1539233B1 (en) 2001-07-12 2011-04-27 FOOTE, Jefferson Super humanized antibodies
GB0228832D0 (en) 2002-12-10 2003-01-15 Novartis Ag Organic compound
GB0318727D0 (en) 2003-08-08 2003-09-10 Smithkline Beecham Corp Novel compounds
DE10338136A1 (de) 2003-08-15 2005-03-24 European Molecular Biology Laboratory Zentrifuge und ein Träger zur Verwendung in einer Zentrifuge
GB0321997D0 (en) 2003-09-19 2003-10-22 Novartis Ag Organic compound
SI1711530T1 (sl) * 2003-12-22 2010-01-29 Glaxo Group Ltd Imunoglobulini, ki nevtralizirajo NogoA, za zdravljenje nevroloških bolezni
EP1761561B1 (en) * 2004-01-20 2015-08-26 KaloBios Pharmaceuticals, Inc. Antibody specificity transfer using minimal essential binding determinants
US7973139B2 (en) * 2004-03-26 2011-07-05 Human Genome Sciences, Inc. Antibodies against nogo receptor

Also Published As

Publication number Publication date
DK1960429T3 (da) 2012-09-24
BRPI0619855A2 (pt) 2011-10-25
SI1960429T1 (sl) 2012-09-28
UA96279C2 (ru) 2011-10-25
ES2389380T3 (es) 2012-10-25
HK1119720A1 (en) 2009-03-13
CA2633501A1 (en) 2007-06-21
NZ569143A (en) 2011-08-26
EA200801343A1 (ru) 2008-12-30
US20130287781A1 (en) 2013-10-31
US20100221260A1 (en) 2010-09-02
EA015536B1 (ru) 2011-08-30
IL192086A0 (en) 2008-12-29
KR101355118B1 (ko) 2014-02-06
WO2007068750A3 (en) 2007-11-29
CR10099A (es) 2008-09-22
KR20080080644A (ko) 2008-09-04
ZA200906162B (en) 2010-05-26
AU2006325228B2 (en) 2011-12-15
MA30041B1 (fr) 2008-12-01
EP2228391A3 (en) 2010-12-29
WO2007068750A2 (en) 2007-06-21
EP1960429A2 (en) 2008-08-27
CA2633501C (en) 2015-03-31
JP2009519025A (ja) 2009-05-14
EP2228391A2 (en) 2010-09-15
HRP20120684T1 (hr) 2012-09-30
AU2006325228A1 (en) 2007-06-21
US8362208B2 (en) 2013-01-29
NO20082699L (no) 2008-09-08
EP1960429B1 (en) 2012-06-27
CN101374863A (zh) 2009-02-25
TW200801038A (en) 2008-01-01
TWI378940B (en) 2012-12-11
MY149492A (en) 2013-09-13
JP5015949B2 (ja) 2012-09-05
GB0525662D0 (en) 2006-01-25
ZA200805111B (en) 2009-12-30
AR057239A1 (es) 2007-11-21
PE20071099A1 (es) 2007-11-22
JO2795B1 (en) 2014-03-15
PT1960429E (pt) 2012-09-25
CY1113094T1 (el) 2016-04-13
CN101374863B (zh) 2013-05-29

Similar Documents

Publication Publication Date Title
ZA200805111B (en) Immunoglobulins directed against NOGO
ZA201306105B (en) DUAL VARIABLE DOMAIN IMMUNOGLOBULIN (DVD-lg)
GB0523969D0 (en) Inductivwe component
GB0600488D0 (en) Immunoglobulins
EP1922247A4 (en) PROJECTOR
GB2440699B (en) Combination dolly-pallet
EP1907423A4 (en) CATALYTIC IMMUNOGLOBULINS
GB0517487D0 (en) Antibodies
EP1934716A4 (en) COMPONENT ARCHITECTURE
GB0523041D0 (en) Combination
IL188282A0 (en) Immunoglobulines
GB0523040D0 (en) Combination
TWM284151U (en) Sliding component
GB0502992D0 (en) The ballcaster
TWM290363U (en) Blocking component
GB0720953D0 (en) Slide
EP1896047A4 (en) ANTI-GFRALPHA3 ANTIBODIES
GB0505489D0 (en) Antibodies
GB0513766D0 (en) Immunoglobulins
GB2438867B (en) Luminaire
GB0512278D0 (en) Antibodies
GB0505054D0 (en) Antibodies
GB0523899D0 (en) The one
GB0511610D0 (en) The motor-roll-off
GB0525448D0 (en) Immunoglobulins